WOODBRIDGE, ON. - Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on cardiovascular disease and overall health, is pleased to announce that the company will be exhibiting at the European Society of Cardiology (ESC) Congress 2012 in Munich, Germany August 25-29, 2012, Hall A2 Booth #B440. The ESC Congress is the largest meeting of Cardiologists in Europe and a forum for the latest research in cardiovascular disease, both clinical and experimental. It is a renowned Medical Trade Show that attracts delegates from all over the world.

The scientific data demonstrating the superiority of VASCAZEN™'s formulation recently presented at the 17th World Congress on Heart Disease - Annual Scientific Sessions has been expanded and these additional findings will be presented at the ESC Congress. The presentation will take place on Monday August 27, 2012 at 16:30 in Tripoli Village 1. The study, entitled The highly purified EPA:DHA 6:1 product evokes potent endothelium-dependent relaxations of porcine coronary artery rings via the redox-sensitive PI3-kinase/Akt-dependent phosphorylation of eNOS, was authored by F. Zgheel, M. Alhosin, C. Auger and V.B. Schini-Kerth and conducted at the University of Strasbourg, Illkirch and France.

"Exhibiting at the ESC Congress is an important step in the introduction of VASCAZEN™ to the European market" stated Dr. George Jackowski, Chairman and Chief Scientific Officer of Pivotal Therapeutics. "We are absolutely delighted that the Scientific Study presented last month in Toronto, demonstrating the superiority of VASCAZEN™'s unique formulation, was chosen for presentation to this international audience. We are eager to share these findings, especially given the importance to patients with Coronary Heart Disease."

Source: Pivotal Therapeutics Inc.